Encontrados 6 documentos, a visualizar página 1 de 1

Ordenado por Data

Erythropoietin doping as cause of sudden death in athletes: an experimental study

Piloto, N.; Teixeira, H.M.; Teixeira-Lemos, E.; Parada, B.; Garrido, P.; Sereno, J.; F. Pinto, A.F.; Costa, Elísio; Belo, L.; Santos-Silva, A.

Aims: To evaluate the cardiovascular (CV) effects of rhEPO treatment in rats under chronic aerobic exercise and to assess the probable cause of sudden death in one rat. Protocol: Male Wistar rats: control - sedentary; rhEPO - 50 IU/Kg/3xwk; swimming (EX) -1 hr, 3x/wk; EX+EPO. Hematology, catecholamines and serotonin, redox status and inflammation, were assessed. One rat of EX+EPO group suffered a sudden death e...


Hemorheological and cardiovascular effects of erythropoietin in a rat model of ...

Piloto, N.; Teixeira, HM; Garrido, P.; Teixeira-Lemos, E.; Teixeira, M.; Parada, B.; Sereno, J.; Pinto, R .; Alves, R.; Santos, P.; Romão, AM; Nunes, S.

Recombinant human erythropoietin (rhEPO) has been therapeutically used for correction of anaemia. However, due to the increase in circulating red blood cells (RBCs) it promotes, thus increasing oxygen delivery to muscles and improving performance in sport, it has been also illegally used as sports doping. Besides the well known increase of hematocrit and blood viscosity; which might cause serious complications ...


Caracterização hemorreológica, bioquímica e cardiovascular num modelo de doença...

Garrido, P.; Costa, Elísio; Teixeira-Lemos, E.; Parada, B.; Teixeira, M.; Santos, P.; Piloto, N.; Sereno, J.; Alves, R.; Pinto, R.; Rocha-Pereira, P.

Chronic kidney disease (CKD) is a major public health problem throughout the world. The major outcomes include a rapid progression, with development of anaemia and serious complications, namely thromboembol ic and cardiovascular events. The pathophysiological alterations depend on the CKD degree, which will also determine the moment to initiate hemodialysis and recombinant erythropoietin (rhEPO) therapies Thus,...


Hypertension induced by immunosuppressive drugs: a comparative analysis between...

Reis, F; Parada, B; Teixeira de Lemos, E; Garrido, P; Dias, A; Piloto, N; Baptista, S; Sereno, J; Eufrásio, P; Costa, E; Rocha-Pereira, P

The purpose of this study was to compare the effects of sirolimus (SRL) vs cyclosporine (CsA) concerning the cardiovascular mechanisms hypothetically contributing to hypertension development. Three rat groups were studied: control (vehicle), CsA (5 mg/kg/d), and SRL (1 mg/kg/d). The following parameters were evaluated after 7 weeks of treatment: blood pressured (BP) and heart rate (HR; tail cuff), lipid profile...


Recombinant human erythropoietin therapy has beneffical cardio-renal effects on...

Garrido, P.; Reis, F.; Costa, Elísio; Parada, B.; Piloto, N.; Sereno, J.; Teixeira, A.; Pinto, R.; Figueiredo, A.; Alves, R.; Rocha-Pereira, P.

This study aimed to assess the cardio-renal effects of rhEPO therapy on an animal model of moderate chronic renal failure (CRF). Four groups (n =7) of male rat were evaluated during a 12-week follow up period: control; rhEPO: 50 IU/Kg/wk; CRF: two-stage 3/, nephrectomy; CRF+ rhEPO (start after the 3'd wk of surgery). Renal function, haematology and serum inflammation and redox status were assessed. rhEPO treatm...


Hypertension induced by immunosuppressive drugs: a comparative analysis between...

Reis, F.; Parada, B.; Lemos, E. Teixeira de; Garrido, P.; Dias, A.; Piloto, N.; Baptista, S.; Sereno, J.; Eufrásio, P.; Costa, Elísio; Rocha-Pereira, P.

The purpose of this study was to compare the effects of sirolimus (SRL) vs cyclosporine (CsA) concerning the cardiovascular mechanisms hypothetically contributing to hypertension development. Three rat groups were studied: control (vehicle), CsA (5 mg/kg/d), and SRL (1 mg/kg/d). The following parameters were evaluated after 7 weeks of treatment: blood pressured (BP) and heart rate (HR; tail cuff), lipid profile...


6 Resultados

Texto Pesquisado

Refinar resultados

Autor











Data



Tipo de Documento



Recurso



Assunto















    Financiadores do RCAAP

Fundação para a Ciência e a Tecnologia Universidade do Minho   Governo Português Ministério da Educação e Ciência Programa Operacional da Sociedade do Conhecimento União Europeia